Building the world’s largest digital hospital for neurological challenges

Project Information

VR4NEURO

Grant agreement ID: 190161361

DOI

10.3030/190161361

Project closed

EC signature date 28 October 2022

Start date 1 November 2022

End date 31 March 2025

Funded under

• The European Innovation Council (EIC)

Total cost

€ 3 565 875,00

EU contribution

€ 2 496 112,00

Coordinated by

PEILI VISION OY
Finland

Periodic Reporting for period 2 - VR4NEURO (Building the world’s largest digital hospital for neurological challenges)

Reporting period: 2023-11-01 to 2025-03-31

Summary of the context and overall objectives of the project

Peili Vision was founded in 2015 based on a vision to help people rehabilitate after traumatic health events, such as stroke. By combining VR technology, artificial intelligence, gamification and the latest science in neurorehabilitation, our mission is to empower every patient to get access to healthcare and train in the most effective way and as frequently as possible from the comfort of their own home. Our evidence-based novel evaluation and rehabilitation methods enable feedback and progress tracking remotely. Remote approach addresses the key bottleneck in this field: lack of professionals, which is why currently the cost of healthcare services is very high while the availability is very limited, especially in rural and remote areas. Our first product was designed for speech therapy. With the support of the EIC funding, we were able to expand our product-service offering to cover the entire patient care path, from remote evaluation to AI-designed therapy programs and medication evaluation.

The current care path of different neurological disorders, such as ADHD, Autism, Alzheimer and Aphasia, is resource-intensive and inefficient in diagnosing and treating the patients. There is currently no way to screen larger masses of people effectively. The people that are subjectively observed by themselves, parents, teachers etc. may seek out diagnosis. This subjective observation is not reliable and will fill the limited resources with patients not having neurological diseases and miss a lot of patients that would need help but aren’t observed early. We provide quick and efficient tools to help screen masses and enable patients to move on the care path they need.

In the diagnostics phase, our tools help to reach diagnosis faster and more reliably. At the moment, psychiatrists and doctors utilize slow and inaccurate pen and paper -tests to help make diagnoses. By introducing objective, reliable and accurate diagnostics tools we are able to evolve and improve the diagnosis path greatly.

After screening and diagnostics, the care path moves on to treatment, medication and evaluation. Our innovations help in all of these. Through our web platform, doctors can assess the effect of medication and assess the treatment more accurately and react faster to changes in the patient's performance in their everyday life.

During the project, we have developed a robust tool to help diagnosing and rehabilitate patients. The project allowed us to put product development on the forefront of technological advancement in our field by implementing clustering models to derive better metrics and models and eventually bringing AI-based solutions helping us to be the most accurate solution and to be the best support for patients.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

The VR4NEURO project developed a web based solution for diagnostics and care management and virtual reality (VR) based adaptive rehabilitation to transform neurological care. Technologically, the project achieved several milestones. A diagnostic tool was built and clinically validated against gold standards, reaching up to 98% sensitivity in ADHD detection with an AUC of 88%, leveraging a “combined score” metric for improved diagnostic reliability. The rehabilitation component evolved into an adaptive system using AI to personalize exercises based on user performance and diagnostic data, notably targeting executive function deficits in ADHD and related conditions.

The web portal was finalized for clinician use, supporting remote monitoring, test management, and reporting. Clinicians can access both medical and family-friendly reports, enhancing communication and care decisions. Additionally, a CE Class IIa medical certification was secured for the diagnostic tool, supported by a robust Quality Management System (QMS) aligned with ISO 13485 standards.

On the data integration front, the platform achieved readiness for interoperability with Electronic Patient Record (EPR) systems using the HL7 FHIR framework, tested successfully in simulated environments. The Pathway Management System (PMS), initially conceived as a flagging tool, was extended into a system-wide care pathway manager, offering real-time insights and clinical decision support.

These achievements position the VR4NEURO platform as a clinically validated, scalable, and interoperable digital toolset for neurological diagnostics and rehabilitation.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The VR4NEURO project has successfully delivered a clinically validated, AI-powered platform for diagnostics and adaptive rehabilitation of neurological conditions. The diagnostic tool demonstrated 98% sensitivity and an AUC of 88%, validated against the gold-standard CPT, enabling accurate, objective ADHD assessments with minimal false negatives. The adaptive rehabilitation system leverages AI to personalize therapy in real time, based on diagnostic and behavioral data, targeting executive function challenges with a special focus on children with ADHD. A web portal for clinicians supports remote monitoring, personalized reporting, and secure patient management, and platform interoperability with EPR systems was achieved via HL7 FHIR, validated in the Finnish Kanta sandbox environment.

The project’s outcomes also include CE Class IIa certification and ISO 13485 compliance, confirming readiness for clinical deployment across Europe. The introduction of the Pathway Management System, evolved from a simple flagging feature, now provides real-time oversight of patient journeys, offering clinicians decision support and health systems a means to optimize care delivery.

The platform’s impact is multi-fold: enabling earlier intervention, reducing diagnostic bottlenecks, enhancing rehabilitation adherence, and facilitating data-driven care coordination. For broader uptake, key needs include: (1) expanded clinical studies covering additional neurodevelopmental profiles (e.g. ASD), (2) demonstration pilots in diverse health systems, (3) support for international market access and regulatory harmonization (e.g. FDA), and (4) sustained IPR management to protect software and algorithm innovations.

Further, financing is essential to scale commercial readiness and integrate the platform with national health systems. Engaging with payers and regulators will support reimbursement alignment and accelerate clinical adoption. VR4NEURO now stands as a validated, scalable foundation for the digital transformation of neurodiagnostics and rehabilitation, poised for international growth and long-term impact.

Logo